Clinical Trial

A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The researchers are doing this study is to find the highest dose of cytokine-induced memory-like (CIML) natural killer (NK) cells in combination with the drug atezolizumab that causes few or mild side effects in people with relapsed/refractory acute myelogenous leukemia (AML). The researchers will also look at whether the treatment combination works against participants' cancer.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-05-30; most recent amendment 2026-06-16.
Trial Details
NCT Number NCT07011004
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Genentech, Inc.
Conditions Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
Enrollment 18 participants
Start Date 2025-05-30
Primary Completion 2028-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-17